Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
8 Results for "
DS-8201a
" in MedChemExpress (MCE) Product Catalog:
Products (8)
8 Results for "DS-8201a" in MCE Product Catalog:
14
14 Publications Verification
Synonyms: Exatecan derivative for ADC
Target:
Research Areas:
DXd (Exatecan derivative for ADC) is a potent DNA topoisomerase I inhibitor, with an IC50 of 0.31 μM, used as a conjugated drug of HER2-targeting ADC (DS-8201a).
9
9 Cited Publications
Synonyms: T-DXd; DS-8201; DS-8201a
9
9 Cited Publications
Synonyms: T-DXd (solution); DS-8201 (solution); DS-8201a (solution)
Cat. No.: HY-13631DS
Purity: 98.84%
Synonyms: Exatecan-d5 derivative for ADC
Cat. No.: HY-138298B
CAS No.: 1826843-81-5
Synonyms: T-DXd (DAR2); DS-8201 (DAR2); DS-8201a (DAR2)
Target:
Research Areas:
Trastuzumab deruxtecan (DAR2) (T-DXd (DAR2); DS-8201 (DAR2); DS-8201a (DAR2)) is a low-drug-load derivative control preparation of Trastuzumab deruxtecan (HY-138298A) with a drug-to-antibody ratio (DAR) of 2. Trastuzumab deruxtecan (T-DXd; DS-8201a; DS-8201) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .
Cat. No.: HY-138298C
CAS No.: 1826843-81-5
Synonyms: T-DXd (DAR4); DS-8201 (DAR4); DS-8201a (DAR4)
Target:
Research Areas:
Trastuzumab deruxtecan (DAR4) (T-DXd (DAR4); DS-8201 (DAR4); DS-8201a (DAR4)) is a low-drug-load derivative control preparation of Trastuzumab deruxtecan (HY-138298A) with a drug-to-antibody ratio (DAR) of 4. Trastuzumab deruxtecan (T-DXd; DS-8201a; DS-8201) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .
Cat. No.: HY-138298D
CAS No.: 1826843-81-5
Synonyms: T-DXd (DAR6); DS-8201 (DAR6); DS-8201a (DAR6)
Target:
Research Areas:
Trastuzumab deruxtecan (DAR6) (T-DXd (DAR6); DS-8201 (DAR6); DS-8201a (DAR6)) is a low-drug-load derivative control preparation of Trastuzumab deruxtecan (HY-138298A) with a drug-to-antibody ratio (DAR) of 6. Trastuzumab deruxtecan (T-DXd; DS-8201a; DS-8201) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .
Cat. No.: HY-13631DS1
CAS No.: 2760715-90-8
Synonyms: Exatecan derivative for ADC-d2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
